Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female outpatients, age 18-75 years;~2. Presence of current DSM-IV nicotine dependence and PG for at least 6 months duration;~3. Stable psychotropic drug dose for a period of at least 3 months prior to study entry;~4. Completion of complete blood count, urinalysis, liver function tests, thyroid function tests, and pregnancy test with no evidence of significant lab abnormalities;~5. Signed informed consent~Exclusion Criteria:~1. Subjects who are currently receiving individual or group therapy specifically for nicotine dependence or PG symptoms;~2. Currently receiving pharmacotherapies for either nicotine dependence or pathological gambling;~3. Subjects who have started attending Gamblers Anonymous within the 3 months prior to study initiation;~4. Subjects who have an unstable and significant medical illness;~5. Current clinically significant suicidality (score or 3 or 4 on item 3 of the Hamilton Depression Rating Scale) or any other disorder requiring immediate intervention;~6. Lifetime history of bipolar disorder type I or II, dementia, or psychotic disorder;~7. Current (past 12 months) DSM-IV substance abuse or dependence (except nicotine dependence);~8. Borderline or antisocial personality disorder based on the SCID-II;~9. Positive urine drug screen at screening;~10. Asthma (given possible worsening of asthma due to NAC);~11. Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent;~12. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential; and~13. Previous treatment with NAC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- N Acetyl Cysteine (Type: EXPERIMENTAL): The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).